Skip to main content
Richard Messmann, MD, Oncology, Brighton, MI

RichardAdamMessmannMD

Oncology • Brighton, MI

Executive Director, Global Development, Prostate Cancer, Amgen Inc.

Join to view full profile

Dr. Messmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Messmann's full profile

Already have an account?

Summary

  • Dr. Richard Messmann is a medical oncologist, biochemist, electrical and computer engineer and clinical research physician with over 25 years of experience in oncology drug development ranging from Phase I-III clinical studies. Dr. Messmann’s career focus is in the development of targeted diagnostic and therapeutic agents for treatment of various cancer indications.

    After completing a medical oncology fellowship at the National Cancer Institute and obtaining an advanced degree in clinical trial management from Duke University, he served as Deputy Associate Director of the NIH/NCI’s Developmental Therapeutics Program (DTP). He has also held executive positions with Advanced Accelerator Applications (AAA, Novartis AG), Endocyte, Eli Lilly & Co., Michigan State University, ProNAi Therapeutics, Apexian Pharmaceuticals and Amgen Inc.

    Dr. Messmann's clinical leadership of the VISION Phase 3 study of Pluvicto (177Lu-PSMA-617) resulted in the regulatory approval of the first successfully developed radio-therapeutic and radio-diagnostic for use in men with advanced metastatic castrate-resistant prostate cancer. The trial results were presented at the ASCO 2021 plenary session with a concurrent publication in the New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/nejmoa2107322).

    He is currently the Executive Medical Director for Global Development of Xaluritamig (AMG 509), an Anti-STEAP1 XmAb 2+1 T-cell therapy against advanced-stage prostate cancer, early details of which were presented at the 2023 Madrid meeting of the European Society of Medical Oncology.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
  • Sparrow Hospital/Michigan State University
    Sparrow Hospital/Michigan State UniversityResidency, Internal Medicine, 1995 - 1997
  • University of Michigan Health System
    University of Michigan Health SystemResidency, Anesthesiology, 1994 - 1995
  • MedStar Health/Georgetown University Hospital
    MedStar Health/Georgetown University HospitalResidency, Anesthesiology, 1993 - 1993
  • Sparrow Hospital/Michigan State University
    Sparrow Hospital/Michigan State UniversityInternship, Internal Medicine, 1991 - 1992
  • Wayne State University School of Medicine
    Wayne State University School of MedicineClass of 1991

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 1995 - 2026
  • VA State Medical License
    VA State Medical License 1993 - 2002

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Apexian Pharmaceuticals Hires Richard Messmann, M.D. As Chief Medical Officer
    Apexian Pharmaceuticals Hires Richard Messmann, M.D. As Chief Medical OfficerOctober 31st, 2016

Professional Memberships

Dr. Richard Messmann, Dr. Richard Messmann, MD, Dr. R Messmann, Dr. Richard Adam Messmann